$BCLI News
Last published 3mo ago
- 3mo agoBCLIBrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireNEW YORK, Aug. 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the
- 1y agoBCLIBrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQBPR NewswireNEW YORK, July 17, 2025 BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that it has received a delisting notification from The...
- 1y agoBCLIFDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment EffectivenessPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
- 1y agoBCLIBrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®PR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced...
- 1y agoBCLIPLURBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical TrialsPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced...
- 1y agoBCLIBrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALSPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced...
- 1y agoBCLIBrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 1y agoBCLIBrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19PR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 1y agoBCLIBrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025PR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 1y agoBCLIBrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development SummitPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its...
- 1y agoBCLIBrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 MeetingPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, in collaboration with...
- 1y agoBCLIBrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALSPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative...
- 1y agoBCLIBrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate UpdatePR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 1y agoBCLIBrainStorm Cell Therapeutics Granted Compliance Extension from NasdaqPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company committed to the development and commercialization of best-in-class ...
- 1y agoBCLIBrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate UpdatePR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today ...
- 1y agoBCLIBrainStorm Issues 2024 Letter to ShareholdersPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a...
- 1y agoBCLIBrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate UpdatePR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today ...
- 1y agoBCLIBrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform TechnologyPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today ...
- 1y agoBCLIBrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024PR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 1y agoBCLIBrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 2y agoBCLIPLURBrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial ManufacturingPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it...
- 2y agoBCLIBrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that on...
- 2y agoBCLIBrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS MeetingPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...
- 2y agoBCLIBrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual SummitPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced...
- 2y agoBCLIBrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS MeetingPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...
- 2y agoBCLIBrainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBCLIBrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 2y agoBCLIBrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate UpdatePR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 2y agoBCLIBCLI Update - Progress Supports Our 10x Plus Value Range PotentialPR NewswireNASDAQ: BCLI READ ACF EQUITY RESEARCH'S UPDATE NOTE HERE READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE –...
- 2y agoBCLIBrainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)Earnings Call Transcripts
- 2y agoBCLIBrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn ProgramPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today ...
- 2y agoBCLIBrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct OfferingPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, ...
- 2y agoBCLIBrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical TrialPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 2y agoBCLIBrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating OfficerPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 2y agoBCLIBCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness ExpectationPR NewswireINITIATION NOTE: BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) is focused on developing autologous mesenchymal stem cell (MSC) therapies for the...
- 2y agoBCLIBrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwnPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present...
- 2y agoBCLIBrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 2y agoBCLIBrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwnPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 2y agoBCLIBrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value RulePR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegenerative diseases, today...
- 2y agoBCLIBrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALSPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...
- 2y agoBCLIBrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALSPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 2y agoBCLIBrainStorm Cell Therapeutics to Provide Update on NurOwn ProgramPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it...
- 2y agoBCLIBrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate UpdatePR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 2y agoBCLIBrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific ConferencePR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 2y agoBCLIBrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALSPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 2y agoBCLIBrainStorm Cell Therapeutics to Present at European Life Sciences CEO ForumPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
- 2y agoBCLIBRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their OptionsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Brainstorm Cell Therapeutics Inc....
- 2y agoBCLIBRAINSTORM SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their OptionsGlobeNewswireIf you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson
- 2y agoBCLIBrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder TreatmentsPR NewswireBrainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided...
- 2y agoBCLIBRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their OptionsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Brainstorm Cell Therapeutics Inc....